article thumbnail

Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

Bio Pharma Dive

Kelonia will receive $40 million upfront through a partnership to develop “off-the-shelf” cell therapies for cancer.

In-Vivo 291
article thumbnail

Companies agree $800m deal for off-the-shelf in vivo CAR-T cell therapy

Drug Discovery World

Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. The post Companies agree $800m deal for off-the-shelf in vivo CAR-T cell therapy appeared first on Drug Discovery World (DDW).

In-Vivo 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

‘In vivo’ cell therapy: expanding beyond CAR-T

Bio Pharma Dive

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

In-Vivo 359
article thumbnail

Ensoma buys a startup to advance ‘in vivo’ cell therapy work

Bio Pharma Dive

The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.

In-Vivo 310
article thumbnail

FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

Bio Pharma Dive

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

article thumbnail

Single-course in vivo base editing therapy proven to lower cholesterol

Drug Discovery World

Verve-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. “Of The post Single-course in vivo base editing therapy proven to lower cholesterol appeared first on Drug Discovery World (DDW).

In-Vivo 52
article thumbnail

Sygnature Discovery launches in vivo inflammation model and includes kidney and neuroinflammation

BioPharma Reporter

Sygnature Discovery has launched an in vivo inflammation model, that the company says is âexciting but only the beginningâ of understanding life-limiting neuroinflammatory conditions.

In-Vivo 52